Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

January 31, 2018

Study Completion Date

June 30, 2018

Conditions
Hodgkin Lymphoma
Interventions
BIOLOGICAL

Evaluate the improvement in response from the end of anti-PD-1 monotherapy

Evaluate the improvement in response from the end of anti-PD-1 monotherapy to the first evaluation after introduction of CT alone (Group 1) or combined with anti-PD-1 (Group 2).

Trial Locations (1)

Unknown

Centre Hospitalier Lyon Sud, Pierre-Bénite

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT03664323 - Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter